| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| dihydroergotamine | alpha-1 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-1 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-1 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-2a adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-2 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-2 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | alpha-2 adrenergic receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | beta-3 adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | dopamine d2 receptor | small molecule | Successful target | TTD , drugbank , DGIDB | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.04 | approved,investigational | agonist |
| dihydroergotamine | dopamine d3 receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | dopamine d4 receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 1b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.86 | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 1d | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
1.33 | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 1e | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.24 | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 1f | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.27 | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 2b | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 2c | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| dihydroergotamine | 5-hydroxytryptamine receptor 4 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Basilar-Type Migraine[MeSHID:D020325] Episodic Cluster Headache[MeSHID:D003027] Aura[MeSHID:D004827] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | agonist |
| click here to return to the previous page | ||||||||